DOCSLIB.ORG

BULGARIA New Development, Trends and In-Depth Information on Selected Issues

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Focal Point Logo 2013 NATIONAL REPORT (2012 data) TO THE EMCDDA by the Reitox National Focal Point BULGARIA New Development, Trends and in-depth information on selected issues REITOX Part A: New Developments and Trends 1. Drug policy: legislation, strategies and economic analysis 2. Drug use in the general population and specific targeted-groups 3. Prevention 4. Problem Drug Use 5. Drug-related treatment: treatment demand and treatment availability 6. Health correlates and consequences 7. Responses to Health Correlates and Consequences 8. Social correlates and social reintegration 9. Drug-related crime, prevention of drug related crime and prison 10. Drug Markets 2 1. Drug policy: legislation, strategies and economic analysis Within the framework of this section the following main topics will be reviewed: Legislative framework; National action plan, strategy, evaluation and coordination; Economic analysis; Legislative framework Acts, regulations, directives or guidelines in the sphere of drug addictions and drugs (supply and demand) In 2012 a total of nine amendments of the legislative regulation of the Republic of Bulgaria were adopted, including the adoption of two regulations and of seven amendments of the acts and legal regulations in the sphere of addictions. 1. On 20.06.2012 Regulation № 2 was adopted of the terms and conditions of implementing programmes for treatment with agonists and agonist-antagonists of individuals dependent on opioids. 1 By virtue of this regulation the following items are laid down: The terms and conditions for issuing an authorization for the implementation of programmes for treatment with agonists and agonist-antagonists of individuals dependent on opioids. The requirements for the individuals who can lead programmes and the requirements for the healthcare facilities where the programmes can be implemented. The medical products containing agonists and agonist-antagonists which may be used in the programmes, and which are described in Annex № 1. In Annex № 1 medical products are included containing opiate agonists and agonist- antagonists, which according to their short characteristic, are used for the treatment of dependence on opioids. In Annex № 1 of the regulation the medical product Buprenorphine is included, for which there has been a marketing authorization in the country since 2008. The option for the Ministry of Health to provide solely the medical product Methadone funded by the republican budget under the terms of Regulation № 34/2005 on the terms of payment from the republican budget for the treatment of Bulgarian citizens for diseases not included in the mandatory health insurance and to provide it to the healthcare facilities which have been granted a permission for implementing the programmes, pursuant to Art. 16, Para. 1 of the Regulation. 1 Regulation № 2 on the terms and conditions of implementing programmes for treatment with agonists and agonist-antagonists of individuals dependent on opioids of the Narcotic Substances and Precursors Control Act (NSPCA) (promulgated in the SG, issue 49 of 29.06.2012) 3 The compliance of the activity implemented with Regulation № 24 of 2004 on the ratification of “Psychiatry” medical standard. The requirements for the storing of the medical products containing opiate agonists and agonist-antagonists, the book-keeping of the medical products containing opiate agonists and agonist-antagonists used in the programmes. The control of observing the requirements of the Regulation is maintained by the Ministry of Health, by the National Centre for Addictions and by the inspectors on narcotic substances from the Regional Health Inspections (RHI). Pursuant to Art. 10 of the Regulation, the programmes for the treatment with opiate agonists and agonist-antagonists implement their activity in accordance with Regulation № 24 of 2004 for the ratification of “Psychiatry” medical standard. Regulation № 2/2012 revokes Regulation № 24/2000 on the terms and conditions for implementing substitution and maintenance programmes for harm reduction concerning drug dependent individuals. On grounds of § 1, Para. 1 of Regulation № 2/2012 the healthcare facilities, which have been granted authorization to implement substitution and maintenance programmes pursuant to Regulation № 24/2000 on the terms and conditions of implementing substitution and maintenance programmes for harm reduction of individuals dependent on narcotic substances are brought in compliance with the requirements of Regulation № 2/2012 and submit papers for the renewal of the authorization they have. 2. Again on 20.06.2012 Regulation amending Regulation № 24 of 2004 was adopted for the ratification of “Psychiatry” medical standard, section 7 - ”Addiction treatment” 2. Under this amendment the rules for the “Treatment of the opioid addiction syndrome by opiate agonists and agonist-antagonists” are regularized. The decrees of this regulation have been synchronized by Regulation № 2. 3. A project to amend the Tariff of Taxes collected for the issuing, amendment or renewal of authorizations, permits and certificates for registration under the Narcotic Substances and Precursors Control Act (NSPCA). 4. A project to amend Regulation № 21/2000 on the requirements for the documents and the accounting when implementing activities with narcotic substances and their preparations was also prepared; 5. A project was also prepared to amend Regulation № 55/2012 on the terms and conditions of issuing licenses for activities with narcotic substances for medical purposes included in Annex № 2 and Annex № 3 of the NSPCA; 6. A project was also prepared to amend Regulation № 3/2001 on the destruction of legally produced, acquired and stored narcotic substances and medical products containing narcotic substances; 7. A project was also prepared to amend Regulation № 7/2001 on the terms and conditions of issuing authorizations for import and export of narcotic substances and their preparations; 2 Regulation to amend Regulation № 24 of the NSPCA (Promulgated in the SG issue 49 of 29.06.2012) 4 8. A project was also prepared to amend Regulation № 20/2001 on the terms and conditions under which the medical products, containing narcotic substances, may be exempt from some control measures; 9. A project was also prepared to amend Regulation № 28/2001 on the terms and conditions under which some healthcare facilities with no pharmacy may purchase, store and allot narcotic substances. 3 Law enforcement The Ministry of Interior (MoI) implements activities meant to protect the civil rights, the national security and the public order. Prevention is among the leading functions and one of the most important ones through which the main tasks of the ministry are implemented. The bodies of the MoI implement general and individual prevention activity, prevent and stop crime and other legal offences, by systematically analyzing the crime-generating factors, by notifying the state bodies, organizations and legal entities about conditions for crime found. On the data of the Ministry of Interior the following actions were undertaken in 2012 for the “Drugs” section: 4 The Regional Directorates of the MoI (RDMoI) have responded to 2020 notifications about drug-related offences. The greatest number of notifications responded to were at the Metropolitan Directorate of the MoI (MDMoI) – (364), RDMoI Plovdiv - (163), RDMoI Blagoevgrad - (149) and RDMoI Veliko Turnovo- (128). 452 operative lawsuits were heard – the greatest number was at the MDMoI (55), RDMoI Burgas (52), RDMoI Plovdiv (45), RDMoI Pleven (23). In 2012 in the country 4,713 individuals were detained for the production of drugs and for drug-dealing. 2,106 of them were detained by the MDMoI, then come RDMoI Plpovdiv, (275), RDMoI Varna (208) and RDMoI Stara Zagora (193). Here it has to be emphasized that the tendency of the last years holds of increasing the number of the individuals detained. In 2012 in the country a total of 2,868 specialized police operations (SPO) were carried out – the greatest number was by the MDMoI (671), RDMoI Varna (208), RDMoI - Sofia (205) and RDMoI Stara Zagora (193). In 2012 a total of 5,179 gathering places for drug use, pubs and recreational establishments were checked- the greatest number by RDMoI Smolyan (679), RDMoI Sofia (462) RDMoI Veliko Turnovo (418) and the MDMoI (415). Here we have to mention again that in comparison to the preceding years an increase of the places checked is observed. 3 Information: Annual Report of the National Council on Narcotic Substances for 2012 4 Report on the work of the bodies of the RD of the MoI of the “Drugs” unit for the period 01.01.2012 - 31.12.2012 5 The number of the school regions checked is 3,936 – the greatest number by RDMoI Smolyan (449), RDMoI Sofia (342), RDMoI Pleven (252) and the MDMoI (295), and the smallest number of school regions checked was by RDMoI Lovech (8) National action plan, strategy, evaluation and coordination National action plan and/or strategy At the third regular session for 2012 of the National Council on Narcotic Substances (NCNS) a report was presented and approved on the implementation of the tasks of the Action Plan of the National Strategy to Combat Drugs for 2011. In the report the degree of implementing the tasks and of achieving the goals evolving from the National Strategy are given. In the sphere of prevention progress has been achieved of the implementation of the activities related to the development of health education at school. The municipal councils on drugs
Recommended publications
  • NOOTROPIL® Piracetam

    NOOTROPIL® Piracetam

    NOOTROPIL® Piracetam QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 800 mg or 1200 mg of piracetam. Each ml of oral solution contains 200 mg of piracetam EXCIPIENTS NOOTROPIL 800 mg and 1200 mg film-coated tablet: Core: Macrogol 6000 - Colloidal anhydrous silica - Magnesium stearate - Sodium croscarmellose Film-coating: Hydroxypropylmethylcellulose - Titanium dioxide (E171) - Macrogol 400 - Macrogol 6000. NOOTROPIL 200 mg/ml oral solution: Glycerol (85%) - Saccharin sodium - Apricot flavour - Caramel flavour - Methyl parahydroxybenzoate - Propyl parahydroxybenzoate - Sodium acetate - Glacial acetic acid - Purified water. PHARMACEUTICAL FORM NOOTROPIL Tablet 800 and 1200 mg: white, oblong, film-coated tablet, with a bisect line, marked N/N on one side and plain on the other side NOOTROPIL Oral Solution 20%: clear colourless solution INDICATIONS 1. Studies carried out in the elderly suffering from loss of memory, vertigo, a lack of concentration or of alertness, changes of mood, a deterioration in behaviour and personal negligence, demonstrate an improvement in symptoms. These symptoms can also provide an early warning of the onset of pathological ageing such as Alzheimer’s Disease, an Alzheimer type of senile dementia, or the dementia produced by multiple cerebral infarcts. 2. NOOTROPIL is advocated in the treatment of sickle-cell vaso-occlusive crises. 3. Studies have shown some improvement in children with learning difficulties associated with the written word, particularly with textual understanding which cannot be explained by intellectual backwardness, inadequate education or by the family environment. The administration of NOOTROPIL does not replace other measures also well adapted to correct these learning difficulties, such as remedial teaching. DOSAGE AND ADMINISTRATION Oral formulations 1 NOOTROPIL should be administered orally, and may be taken with or without food.
  • St. St. Cyril and Methodius National Library

    St. St. Cyril and Methodius National Library

    НАРОДНА БИБЛИОТЕКА “СВ . СВ . КИРИЛ И МЕТОДИЙ ” ST. ST. CYRIL AND METHODIUS NATIONAL LIBRARY бул . “ Васил Левски ” 88, 1037 София , тел . 00359 (2) 988 28 11, факс 00359 (2) 843 54 95 88, Vasil Levski blvd., 1037 Sofia, Bulgaria, phone 00359 (2) 988 28 11, fax 00359 (2) 843 54 95 http://www.nationallibrary.bg; e-mail: [email protected] Director: Prof. Boryana Hristova e-mail: [email protected] ANNUAL REPORT 2003 To Conference of the European National Librarians (CENL) 1. 1. Management of the library: 2003 was jubilee for the National Library of Bulgaria. All efforts of the staff were directed to celebrate with dignity the 125 Anniversary of the Library. The main goal of the celebrations was to put the National Library of Republic of Bulgaria and some of its most serious problems in front of the attention of the Bulgarian society. 2. Funding During 2003 the basis source of finance of the National Library was the subsidy allocated by the Ministry of Culture - 1 454 837 Bulgarian leva (746 070 Euro) – 85,94 % of the whole funding, including 118 410 leva (60 723 Euro) special grant for purchasing new computers. The Library’s own income is 257 479 leva (132 040 Euro) – 14,06 % of the whole funding. The own income was in proportion 67.60 income from provision of services, 26.46 from rents, 5.99 from sponsorship and 0.24 others. The National Library received 15 433 leva (7 914 Euro) sponsorship by private institutions and donations from individuals to purchase valuable collections, and to support publishing, exhibitions and other cultural events.
  • Aniracetam Reduces Glutamate Receptor Desensitization and Slows

    Aniracetam Reduces Glutamate Receptor Desensitization and Slows

    Proc. Natl. Acad. Sci. USA Vol. 88, pp. 10936-10940, December 1991 Neurobiology Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus (non-N-methyl-D-aspartate receptor/synapse) JEFFRY S. ISAACSON*t AND ROGER A. NICOLLtt *Physiology Graduate Program and the Departments of SPharmacology and tPhysiology, University of California, San Francisco, CA 94143-0450 Communicated by Floyd E. Bloom, September 16, 1991 ABSTRACT Aniracetam is a nootropic drug that has been and DL-2-amino-5-phosphonovaleric acid (50 ,uM) were shown to selectively enhance quisqualate receptor-mediated added to the medium to block y-aminobutyric acid type A responses inXenopus oocytes injected with brain mRNA and in (GABAA) receptors and NMDA receptors, respectively. In hippocampal pyramidal cells [Ito, I., Tanabe, S., Kohda, A. & the majority of experiments examining iontophoretic re- Sugiyama, H. (1990) J. Physiol. (London) 424, 533-544]. We sponses, tetrodotoxin (0.5-1 1uM) was included to block have used patch clamp recording techniques in hippocampal sodium-dependent action potentials. Currents were recorded slices to elucidate the mechanism for this selective action. We with an Axopatch 1B amplifier from neurons in the CA1 and find that aniracetam enhances glutamate-evoked currents in CA3 pyramidal cell layers and granule cell layer of the whole-cell recordings and, in outside-out patches, strongly dentate gyrus using the "blind" whole-cell recording tech- reduces glutamate receptor desensitization. In addition, nique (15, 16). Patch electrodes (tip diameter = 2 Ium) aniracetam selectively prolongs the time course and increases contained (in mM) either a CsF (110 CsF, 10 CsCl, 10 Hepes, the peak amplitude of fast synaptic currents.
  • 1Daskalov R Tchavdar M Ed En

    1Daskalov R Tchavdar M Ed En

    Entangled Histories of the Balkans Balkan Studies Library Editor-in-Chief Zoran Milutinović, University College London Editorial Board Gordon N. Bardos, Columbia University Alex Drace-Francis, University of Amsterdam Jasna Dragović-Soso, Goldsmiths, University of London Christian Voss, Humboldt University, Berlin Advisory Board Marie-Janine Calic, University of Munich Lenard J. Cohen, Simon Fraser University Radmila Gorup, Columbia University Robert M. Hayden, University of Pittsburgh Robert Hodel, Hamburg University Anna Krasteva, New Bulgarian University Galin Tihanov, Queen Mary, University of London Maria Todorova, University of Illinois Andrew Wachtel, Northwestern University VOLUME 9 The titles published in this series are listed at brill.com/bsl Entangled Histories of the Balkans Volume One: National Ideologies and Language Policies Edited by Roumen Daskalov and Tchavdar Marinov LEIDEN • BOSTON 2013 Cover Illustration: Top left: Krste Misirkov (1874–1926), philologist and publicist, founder of Macedo- nian national ideology and the Macedonian standard language. Photographer unknown. Top right: Rigas Feraios (1757–1798), Greek political thinker and revolutionary, ideologist of the Greek Enlightenment. Portrait by Andreas Kriezis (1816–1880), Benaki Museum, Athens. Bottom left: Vuk Karadžić (1787–1864), philologist, ethnographer and linguist, reformer of the Serbian language and founder of Serbo-Croatian. 1865, lithography by Josef Kriehuber. Bottom right: Şemseddin Sami Frashëri (1850–1904), Albanian writer and scholar, ideologist of Albanian and of modern Turkish nationalism, with his wife Emine. Photo around 1900, photo- grapher unknown. Library of Congress Cataloging-in-Publication Data Entangled histories of the Balkans / edited by Roumen Daskalov and Tchavdar Marinov. pages cm — (Balkan studies library ; Volume 9) Includes bibliographical references and index.
  • September 25, 2020 Guangzhou Wondfo Biotech Co., Ltd. Joe Shia

    September 25, 2020 Guangzhou Wondfo Biotech Co., Ltd. Joe Shia

    September 25, 2020 Guangzhou Wondfo Biotech Co., Ltd. ℅ Joe Shia Manager LSI International 504 E Diamond Ave., Suite I Gaithersburg, MD 20877 Re: K202567 Trade/Device Name: Wondfo T-Dip® Multi-Drug Urine Test Panel Wondfo T-Dip® Multi-Drug Urine Test Panel Rx Regulation Number: 21 CFR 862.3100 Regulation Name: Amphetamine test system Regulatory Class: Class II Product Code: NFT, NGL, PTH, NFV, NFY, PTG, NGG, LCM, QBF, QAW, NFW Dated: September 2, 2020 Received: September 4, 2020 Dear Joe Shia: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties.
  • IJBCP International Journal of Basic & Clinical Pharmacology Role Of

    IJBCP International Journal of Basic & Clinical Pharmacology Role Of

    Print ISSN: 2319-2003 | Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology doi: 10.5455/2319-2003.ijbcp20131022 Research Article Role of piracetam on cognitive function in epilepsy and with antiepileptics in rats Siddharth R. Chaudhari1, Priti P. Dhande2*, Vijaya A. Pandit2 1Bristol-Myers Squibb India Pvt. ABSTRACT Ltd, Mumbai-13, Maharashtra, Background: To study extent of cognitive impairment by epilepsy & India 2Department of Pharmacology, antiepileptic treatment and evaluate the role of piracetam on it. Bharati Vidyapeeth (DU) Methods: 48 animals were divided into 6 groups: I-Control, II- Topiramate, III- Medical College, Pune- 43, Topiramate+Piracetam, IV-Valproate, V-Valproate+Piracetam, VI-Piracetam. Maharashtra, India Baseline cognitive functions were measured using Cook’s pole climbing apparatus (CPCA) and Elevated plus maze (EPM). In CPCA, on completion of Received: 10 August 2013 training, number of avoidances (NOA) out of 10 trials were noted while in Accepted: 18 August 2013 EPM, transfer latency (TL) was measured. Kindling was induced by 30mg/kg Pentylenetetrazol (PTZ), i.p. to all groups (except Group I) on alternate days till *Correspondence to: seizures developed. Groups were treated with respective drugs orally for 21 days and cognitive functions measured again. Dr. Priti P. Dhande, Email: [email protected] Results: Significant decrease in NOA & increase in TL was observed after PTZ kindling. Topiramate further significantly impaired NOA and TL whereas © 2013 Chaudhari SR et al. This Valproate significantly reduced NOA in CPCA but increase in TL was not is an open-access article significant. Treatment with Piracetam significantly increased Topiramate, Valproate and PTZ kindling induced decrease in NOA as also significantly distributed under the terms of the Creative Commons reduced Topiramate and PTZ kindling induced increase in TL.
  • History of Modern Bulgarian Literature

    History of Modern Bulgarian Literature

    The History ol , v:i IL Illlllf iM %.m:.:A Iiiil,;l|iBif| M283h UNIVERSITY OF FLORIDA LIBRARIES COLLEGE LIBRARY Digitized by the Internet Archive in 2012 with funding from LYRASIS Members and Sloan Foundation http://archive.org/details/historyofmodernbOOmann Modern Bulgarian Literature The History of Modern Bulgarian Literature by CLARENCE A. MANNING and ROMAN SMAL-STOCKI BOOKMAN ASSOCIATES :: New York Copyright © 1960 by Bookman Associates Library of Congress Catalog Card Number: 60-8549 MANUFACTURED IN THE UNITED STATES OF AMERICA BY UNITED PRINTING SERVICES, INC. NEW HAVEN, CONN. Foreword This outline of modern Bulgarian literature is the result of an exchange of memories of Bulgaria between the authors some years ago in New York. We both have visited Bulgaria many times, we have had many personal friends among its scholars and statesmen, and we feel a deep sympathy for the tragic plight of this long-suffering Slavic nation with its industrious and hard-working people. We both feel also that it is an injustice to Bulgaria and a loss to American Slavic scholarship that, in spite of the importance of Bulgaria for the Slavic world, so little attention is paid to the country's cultural contributions. This is the more deplorable for American influence in Bulgaria was great, even before World War I. Many Bulgarians were educated in Robert Col- lege in Constantinople and after World War I in the American College in Sofia, one of the institutions supported by the Near East Foundation. Many Bulgarian professors have visited the United States in happier times. So it seems unfair that Ameri- cans and American universities have ignored so completely the development of the Bulgarian genius and culture during the past century.
  • Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease

    Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease

    LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES REVIEW ARTICLE Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease Cheryl Waters ABSTRACT: Extensive recent literature on drugs used to enhance cognitive functioning, reflects the growing social problem of dementia. Many clinical trials have been undertaken with variable success. In most cases the disorder stud­ ied has been Alzheimer's disease. The pharmacological approach has been designed to rectify the presumed patho­ physiological processes characteristic of the condition. Agents tested include cerebral vasodilators, cerebral metabolic enhancers, nootropics, psychostimulants, neuropeptides and neurotransmitters with a special emphasis on drugs used to enhance cholinergic function. Ethical and practical issues concerning clinical drug trials in dementia will be discussed. RESUME: Stimulation cognitive medicamenteuse: etat de la question dans le traitement de la maladie d'Alzheimer La multiplicity des publications recentes sur les medicaments utilises pour stimuler le fonctionnement cognitif est le reflet du probl&me social sans cesse croissant de la d6mence. Plusieurs essais cliniques ont ete tentes avec des resultats variables. Dans la plupart des cas, la maladie etudiee etait la maladie d'Alzheimer. L'approche pharmacologique a ete con^ue pour corriger les processus physiopathologiques caracteristiques de la maladie. Les agents etudies incluent des vasodilatateurs cerebraux, des stimulants metaboliques cerebraux, des agents nootropes, des agents neurotropes,
  • Piracetam from Wikipedia, the Free Encyclopedia

    Piracetam from Wikipedia, the Free Encyclopedia

    Piracetam From Wikipedia, the free encyclopedia Systematic (IUPAC) name 2-oxo-1-pyrrolidineacetamide Clinical data Breinox, Dinagen, Lucetam, Nootropil, Nootropyl, Trade names Oikamid, and many others AHFS/Drugs.com International Drug Names Pregnancy cat. ? Legal status POM (UK) Routes Oral and parenteral Pharmacokinetic data Bioavailability ~100% Half-life 4 - 5 hr Excretion Urinary Identifiers CAS number 7491-74-9 ATC code N06 BX03 PubChem CID 4843 ChemSpider 4677 UNII ZH516LNZ10 KEGG D01914 ChEMBL CHEMBL36715 Chemical data Formula C6H10N2O2 SMILES eMolecules & PubChem InChI Piracetam (sold under many brand names) is a nootropic drug. Piracetam's chemical name is 2-oxo-1- pyrrolidine acetamide; it shares the same 2-oxo-pyrrolidone base structure with 2-oxo-pyrrolidine carboxylic acid(pyroglutamate). Piracetam is a cyclic derivative of GABA. It is one of the group of racetams. Piracetam is prescribed by doctors for some conditions, mainly myoclonus,[1] but is used off-label for a much wider range of applications. Popular trade names for Piracetam in Europe are "Nootropil" and "Lucetam", among many others. In South America, it is made by Laboratorios Farma S.A. and sold under the brand name of Breinox in Venezuela and Ecuador. Contents • 1 Effects • 2 Mechanisms of action • 3 History • 4 Approval and usage • 4.1 Aging • 4.2 Alcoholism • 4.3 Alzheimer's and senile dementia • 4.4 Clotting, coagulation, vasospastic disorders • 4.5 Depression and anxiety • 4.6 Stroke, ischemia and symptoms • 4.7 Dyspraxia and dysgraphia • 4.8 Schizophrenia • 4.9 Preventive for breath-holding spells • 4.10 Closed craniocerebral trauma • 5 Dosage • 6 Side effects • 7 Availability • 8 Notes • 9 See also • 10 References • 11 External links Effects There is very little data on piracetam's effect on healthy people, with most studies focusing on people with seizures, dementia, concussions, or other neurological problems.
  • Interactions with PBC Agents

    Interactions with PBC Agents

    www.hep-druginteractions.org Interactions with PBC Agents Charts created November 2020. Full information available at www.hep-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Obeticholic Ursodeoxycholic Acid Acid Acid Acid Acid Acid Anaesthetics & Muscle Relaxants Antibacterials (continued) Antidepressants Bupivacaine Cloxacillin Agomelatine Cisatracurium Dapsone Amitriptyline Isoflurane Delamanid Bupropion Ketamine Ertapenem Citalopram Nitrous oxide Erythromycin Clomipramine Propofol Ethambutol Desipramine Thiopental Flucloxacillin Desvenlafaxine Tizanidine Gentamicin Dosulepin Analgesics Imipenem Doxepin Aceclofenac Isoniazid Duloxetine Alfentanil Escitalopram Aspirin Levofloxacin Linezolid Fluoxetine Buprenorphine Lymecycline Fluvoxamine Celecoxib Imipramine Meropenem Codeine distribution. for Lithium Methenamine Dexketoprofen Maprotiline Metronidazole Dextropropoxyphene Mianserin Moxifloxacin Diamorphine Milnacipran Diclofenac Nitrofurantoin Mirtazapine Diflunisal Norfloxacin Moclobemide Dihydrocodeine Ofloxacin Nefazodone Etoricoxib Penicillin V Nortriptyline Fentanyl Piperacillin Paroxetine Flurbiprofen Pivmecillinam Sertraline Hydrocodone distribution. for only. Not use ersonal Pyrazinamide Tianeptine Hydromorphone Rifabutin Ibuprofen Trazodone Rifampicin Indometacin
  • National Theatre "Ivan Vazov"

    National Theatre "Ivan Vazov"

    National Theatre "Ivan Vazov" – the cultural heart of Sofia Slide 1: Introduction The Ivan Vazov National Theater is located in the center of Sofia (the capital of Bulgaria). In front of the building is one of the most visited parks in the capital. It's known as the City Garden. The theater, has been chosen to be located near the Tzar’s Palace – former Royal Palace (nowadays the National Art Gallery). Slide 2: For more than 100 years, the Ivan Vazov National Theater has been recognized not only as a stage in Bulgaria, but also as a living, working and large-scale theater, that is aware of the important mission as a national cultural institute. The history of the theater is rich, interesting, contrasting in its rises and crisis, but always firmly connected with the essential changes and directions in the development of national culture and art. Slide 3: History In modernizing Sofia at the end of the 19th century, there was long a talk about the need to build a special building for the state theater, which, as the national poet Ivan Vazov points out, would give better opportunities "for the future greatness of dramatic art in Bulgaria". In December 1898, with a decision by the National Assembly was created a special fund for the construction of the building. Slide 4: The theater was designed by the famous Viennese architects Ferdinand Felner and Herman Helmer, who have already made numerous theatrical buildings in Vienna, Zagreb, Prague and other European cities. The construction started in 1904 on the site of the obsolete “Foundation” wooden playhouse, where previously the first professional troupe "Tear and Laughter" played its performances, and at the end of 1906 the building was completed.
  • Optimized and Validated Flow-Injection Spectrophotometric Analysis of Topiramate, Piracetam and Levetiracetam in Pharmaceutical Formulations

    Optimized and Validated Flow-Injection Spectrophotometric Analysis of Topiramate, Piracetam and Levetiracetam in Pharmaceutical Formulations

    Acta Pharm. 61 (2011) 377–389 Original research paper DOI: 10.2478/v10007-011-0038-y Optimized and validated flow-injection spectrophotometric analysis of topiramate, piracetam and levetiracetam in pharmaceutical formulations GHADA M. HADAD1 Application of a sensitive and rapid flow injection analy- 1 RANDA A. ABDEL-SALAM sis (FIA) method for determination of topiramate, pira- SAMY EMARA2 cetam, and levetiracetam in pharmaceutical formulations 1 Pharmaceutical Analytical Chemistry has been investigated. The method is based on the reac- Department, Faculty of Pharmacy tion with ortho-phtalaldehyde and 2-mercaptoethanol in University of Suez Canal a basic buffer and measurement of absorbance at 295 nm Ismailia 41522, Egypt under flow conditions. Variables affecting the determina- tion such as sample injection volume, pH, ionic strength, 2 Pharmaceutical Analytical Chemistry reagent concentrations, flow rate of reagent and other FIA Department, Faculty of Pharmacy parameters were optimized to produce the most sensiti- Misr International University, Egypt ve and reproducible results using a quarter-fraction fac- torial design, for five factors at two levels. Also, the me- thod has been optimized and fully validated in terms of linearity and range, limit of detection and quantitation, precision, selectivity and accuracy. The method was suc- cessfully applied to the analysis of pharmaceutical prepa- rations. Keywords: topiramate, piracetam, levetiracetam, flow-in- Accepted October 31, 2011 jection analysis Flow injection analysis (FIA) has become a technique of increasing importance in pharmaceutical analysis because of its implicit simplicity, low cost and rapid approach. FIA is a continuous flow method in which a small plug of sample is injected into a flow- ing reagent stream.